ProHost Biotech
Login
Members Home
Home
News & Comments
About Us
Forward Looking Statement
Contact Us
Statement
News and Comments
Biogen Idec Pays Elan $3.25 billion For Tysabri. Do We Leave, Or Stay?
Wednesday, February 06, 2013
More...
Comments (0)
|
Trackbacks (0)
|
Permalink
Previous
1
Next
Recent Posts
THE REAL VALUE OF SEATTLE GENETICS
SAREPTA: What's Going On ?
ImmunoGen Offers New Hopes For Treatment Of Subtypes Of Squamous Cell Carcinomas And Other Difficult-To-Treat Cancers
A Quick Response To ARIAD'S (ARIA) Conference Call
NORTHWEST BIOTHERAPEUTICS: AN EXAMPLE OF REFORM IN THE DRUG APPROVAL PROCESS.
IDERA (IDRA): GOOD NEWS OFFSET SOMEWHAT BY SKEPTICISM NOT PESSIMISM
Biogen Idec Pays Elan $3.25 billion For Tysabri. Do We Leave, Or Stay?
The FDA Approval Of Kynamro™ Promises ISIS A Bright Future Read Also about ALNY; Sarepta, SNY
XOMA: WILL THE LOVE-HATE SKEPTICISM MARRIAGE WITH INVESTORS FINALLY ENDS UP IN A STABLE RELATIONSHIP?
THERAVANCE: BECAME TEMPTING TO INVESTORS ANR TO ITS PARTNER
Abbott Laboratories (ABT)
(1)
ADVENTRIX (ANX)
(1)
Alnylam (ALNY)
(3)
Amgen (AMGN)
(8)
Anadys (ANDS)
(1)
Ariad (ARIA)
(6)
Array Pharmaceuticals (ARRY)
(1)
Benlysta (belimumab)
(1)
Biogen Idec (BIIB)
(2)
Bristol-Myers Squibb (BMY)
(2)
CompuGen (CGEN)
(4)
Cytokinetics (CYTK)
(2)
Dendreon (DNDN)
(7)
Dynavax (DVAX)
(1)
Elan (ELN)
(6)
Endometrial Cancer
(1)
Exelixis (EXEL)
(4)
Genentech
(2)
Gilead (GILD)
(6)
GlaxoSmithKline (GSK)
(2)
Herceptin
(2)
Human Genome Sciences (HGSI)
(2)
Idenix (IDIX)
(2)
IDERA (IDRA)
(1)
Illumina (ILMN)
(4)
ImmunoGen (IMGN)
(10)
Incyte (INCY)
(3)
Intermune (ITMN)
(2)
ISIS (ISIS)
(3)
KERYX (KERX)
(1)
Merck (MRK)
(3)
Micromet (MITI)
(1)
Multiple Myeloma
(1)
Onyx (ONXX)
(4)
OSI (OSIP)
(1)
Pluristem (PSTI)
(1)
Prolor Biotech (PBTH)
(2)
Rapamune
(1)
Regeneron (REGN)
(7)
Revlimid (lenolidamide)
(1)
Ridaforolimus
(1)
Roche (RHHBY)
(2)
Roche (ROCHE)
(1)
Sangamo (SGMO)
(2)
Sanofi (SNA)
(1)
Sanofi (SNY)
(1)
Sanofi-Aventis (SAN)
(2)
Sarepta (SRPT)
(2)
Seattle Genetics (SGEN)
(6)
Sequenom (SQNM)
(7)
SUNESIS PHARMACEUTICALS (SNSS)
(1)
Telaprevir
(1)
Theravance (THRX)
(1)
Trastuzumab-DM1
(1)
Tysabri
(1)
Valeant Pharmaceuticals International (VRX)
(1)
Velcade (bortezomib)
(1)
Vertex (VRTX)
(10)
Xoma (XOMA)
(5)
ZALTRAP™
(1)
Zerenex
(1)
Archive
May 2013 (1)
April 2013 (3)
March 2013 (2)
February 2013 (1)
January 2013 (3)
December 2012 (4)
November 2012 (2)
October 2012 (1)
September 2012 (2)
August 2012 (3)
July 2012 (1)
June 2012 (3)
Tags
Velcade (bortezomib)
Genentech
Dynavax (DVAX)
OSI (OSIP)
Tysabri
Pluristem (PSTI)
Idenix (IDIX)
Regeneron (REGN)
Intermune (ITMN)
Dendreon (DNDN)
Onyx (ONXX)
Xoma (XOMA)
Amgen (AMGN)
CompuGen (CGEN)
Gilead (GILD)
Trastuzumab-DM1
ADVENTRIX (ANX)
Sanofi-Aventis (SAN)
Prolor Biotech (PBTH)
Elan (ELN)
Seattle Genetics (SGEN)
Roche (RHHBY)
Theravance (THRX)
Exelixis (EXEL)
ImmunoGen (IMGN)
Ariad (ARIA)
Roche (ROCHE)
Biogen Idec (BIIB)
Revlimid (lenolidamide)
Sanofi (SNY)
Telaprevir
Sequenom (SQNM)
Endometrial Cancer
Sangamo (SGMO)
Herceptin
Sarepta (SRPT)
Rapamune
Incyte (INCY)
Multiple Myeloma
Micromet (MITI)
Bristol-Myers Squibb (BMY)
ZALTRAP™
Benlysta (belimumab)
Abbott Laboratories (ABT)
Illumina (ILMN)
Array Pharmaceuticals (ARRY)
Valeant Pharmaceuticals International (VRX)
SUNESIS PHARMACEUTICALS (SNSS)
Sanofi (SNA)
Anadys (ANDS)
GlaxoSmithKline (GSK)
Merck (MRK)
Alnylam (ALNY)
IDERA (IDRA)
Zerenex
Cytokinetics (CYTK)
Vertex (VRTX)
Ridaforolimus
KERYX (KERX)
ISIS (ISIS)
Human Genome Sciences (HGSI)
SECURE ZONE LOGIN
Username
Password
Remember Me